{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T23:02:04Z","timestamp":1783551724139,"version":"3.55.0"},"reference-count":19,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,9,11]],"date-time":"2023-09-11T00:00:00Z","timestamp":1694390400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Ipilimumab plus nivolumab therapy is approved for patients with unresectable advanced esophageal squamous cell carcinoma (ESCC). Although a combination of immune checkpoint inhibitors (ICIs), compared to conventional chemotherapy, can improve overall survival in patients with advanced ESCC, this increases the incidence of immune-related adverse events (irAEs). Here, we describe an ESCC case that developed pemphigus vulgaris (PV), an extremely rare cutaneous irAE, during ipilimumab plus nivolumab treatment. The patient achieved a partial response to treatment. The PV was successfully managed after the cessation of ipilimumab and the use of a topical steroid. We should thus re-treat ESCC with nivolumab monotherapy. In the era of ICIs as standard cancer therapeutics, diagnostic criteria for blistering diseases need to be established to properly manage patients with cutaneous irAEs.<\/jats:p>","DOI":"10.3389\/fimmu.2023.1259071","type":"journal-article","created":{"date-parts":[[2023,9,11]],"date-time":"2023-09-11T07:07:40Z","timestamp":1694416060000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":10,"title":["Pemphigus vulgaris as an immune-related adverse event in recurrent metastatic esophageal squamous cell carcinoma treated with ipilimumab plus nivolumab: a case report and literature review"],"prefix":"10.3389","volume":"14","author":[{"given":"Hajime","family":"Nakamura","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aika","family":"Shionoya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yohei","family":"Arihara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naotaka","family":"Hayasaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomohiro","family":"Kubo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makoto","family":"Usami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shintaro","family":"Sugita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hisashi","family":"Uhara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kohichi","family":"Takada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,9,11]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1200\/jco.22.02331","article-title":"Immunotherapy and targeted therapy for advanced gastroesophageal cancer: ASCO guideline","volume":"41","author":"Shah","year":"2023","journal-title":"J Clin Oncol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1056\/EVIDoa2100070","article-title":"Tremelimumab plus durvalumab in unresectable hepatocellular carcinoma","volume":"1","author":"Abou-Alfa","year":"2022","journal-title":"NEJM Evidence"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1056\/EVIDoa2200015","article-title":"Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer","volume":"1","author":"Oh","year":"2022","journal-title":"NEJM Evidence"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2111380","article-title":"Nivolumab combination therapy in advanced esophageal squamous-cell carcinoma","volume":"386","author":"Doki","year":"2022","journal-title":"N Engl J Med"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1007\/s11523-020-00738-6","article-title":"Lessons to be learnt from real-world studies on immune-related adverse events with checkpoint inhibitors: A clinical perspective from pharmacovigilance","volume":"15","author":"Raschi","year":"2020","journal-title":"Target Oncol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1703481","article-title":"Immune-related adverse events associated with immune checkpoint blockade","volume":"378","author":"Postow","year":"2018","journal-title":"N Engl J Med"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1200\/jco.21.01440","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update","volume":"39","author":"Schneider","year":"2021","journal-title":"J Clin Oncol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2018.00268","article-title":"Mucous membrane pemphigoid, bullous pemphigoid, and anti-programmed death-1\/ programmed death-ligand 1: a case report of an elderly wOman with mucous membrane pemphigoid developing after pembrolizumab therapy for metastatic melanoma and review of the literature","volume":"5","author":"Zumelzu","year":"2018","journal-title":"Front Med (Lausanne)"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2019.00249","article-title":"Paraneoplastic pemphigus revealed by anti-programmed death-1 pembrolizumab therapy for cutaneous squamous cell carcinoma complicating hidradenitis suppurativa","volume":"6","author":"Yatim","year":"2019","journal-title":"Front Med (Lausanne)"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.21836","article-title":"Checkpoint inhibitor-associated bullous cutaneous immune-related adverse events: a multicentre observational study","volume":"187","author":"Kawsar","year":"2022","journal-title":"Br J Dermatol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.14601","article-title":"Atypical pemphigus developed in a patient with urothelial carcinoma treated with nivolumab","volume":"46","author":"Ito","year":"2019","journal-title":"J Dermatol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.691980","article-title":"Case report: autoimmune pemphigus vulgaris in a patient treated with cemiplimab for multiple locally advanced cutaneous squamous cell carcinoma","volume":"11","author":"Buquicchio","year":"2021","journal-title":"Front Oncol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1111\/ijd.15405","article-title":"Pemphigus associated with ipilimumab therapy","volume":"60","author":"Schoenberg","year":"2021","journal-title":"Int J Dermatol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.3390\/ijms18122532","article-title":"Paraneoplastic pemphigus: insight into the autoimmune pathogenesis, clinical features and therapy","volume":"18","author":"Paolino","year":"2017","journal-title":"Int J Mol Sci"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2021.04.040","article-title":"Pemphigus and pemphigoid: from disease mechanisms to druggable pathways","volume":"142","author":"Ellebrecht","year":"2022","journal-title":"J Invest Dermatol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2023.1208418","article-title":"Autoimmune bullous dermatoses in cancer patients treated by immunotherapy: a literature review and Italian multicentric experience","volume":"10","author":"Merli","year":"2023","journal-title":"Front Med (Lausanne)"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1111\/cas.13772","article-title":"Neoadjuvant chemotherapy with docetaxel, nedaplatin, and fluorouracil for resectable esophageal cancer: a phase II study","volume":"109","author":"Ohnuma","year":"2018","journal-title":"Cancer Sci"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1111\/cup.13312","article-title":"Suprabasal acantholytic dermatologic toxicities associated checkpoint inhibitor therapy: a spectrum of immune reactions from paraneoplastic pemphigus-like to Grover-like lesions","volume":"45","author":"Chen","year":"2018","journal-title":"J Cutan Pathol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1177\/1203475420943260","article-title":"Cutaneous Immune-Related Adverse Events (irAEs) to Immune Checkpoint Inhibitors: a dermatology perspective on management","volume":"25","author":"Muntyanu","year":"2021","journal-title":"Cutan Med Surg"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2023.1259071\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,11]],"date-time":"2023-09-11T07:07:42Z","timestamp":1694416062000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2023.1259071\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,11]]},"references-count":19,"alternative-id":["10.3389\/fimmu.2023.1259071"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2023.1259071","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,11]]},"article-number":"1259071"}}